Our Svar representatives will teach more about the products we're developing and the services we are offering to address the obstacles and analytical challenges involved in developing Biologics!
To book a personal meeting with one of our representatives and find out how we can help streamline your future projects – please contact email@example.com
Assay development within the field of AAV therapies; engineering iLite cell lines for specific and general assays
Tuesday, Nov 2, 3:20 pm - 3:35 pm (CET)
Cell and Gene Therapy Analytics
Jordi Rodó, Ph.D. ,Research Scientist at Svar Life Science AB
The analytical demands of cell and gene therapies can be extremely challenging throughout the development phases. The use of bioassays facilitates the different developmental phases as they can be used to determine key parameters including: vector potency, product identity or determination/titration of neutralizing antibodies. Here, we present different strategies for the development of reliable bioassays for specific or more global use by showcasing a selection of our engineered iLite® cells.
After the presentation we encourage you to meet our speaker, who is present in-person at the event, to address any questions/comments in real-time.
P2-26: ”A Novel Method for Quantification of ADCC Activity Based on the Use of Engineered Effector Cells and a Series of Matching Target Cells”
On-site: Poster Session 2, Wednesday afternoon – Thursday (During Refreshment Breaks)
On-line: VIRTUAL POSTER CHAT ,Thursday, 4 November 12:55 – 13:45
Therese Segerstein, Product Manager at Svar Life Science AB
In this poster, we present a novel ADCC effector cell expressing the V-variant of the FcγIIIa receptor and the firefly luciferase (FL) reporter gene under the control of a chimeric promotor incorporating recognition sequences for the principal transcription factors involved in the FcγIIIa signal transduction, together with novel target cells overexpressing a constant high level of a specific antigen/drug target. Homologues control target cells, in which the specific target gene has been invalidated by genome editing, provide an ideal control. Furthermore, the cells contain a normalization gene rending ADCC activity independent of cell number and serum matrix effect.
Our poster-presenter will share our poster live, allowing you to ask questions and interact directly with our expert - please come and visit!